IGF-1 LR3 is an insulin-like growth factor 1 analogue with an arginine substitution at position three and a 13-amino-acid N-terminal extension. Those modifications reduce binding to IGF binding proteins, giving it a far longer active half-life than native IGF-1 — the characteristic most often examined in IGF signalling research. This 0,1mg vial suits research with medium to larger volume requirements.
Third-party testing covers purity of ≥99.4%, compound identification by LC-MS, and endotoxin levels below 0.5 EU/mg.
The dry vial is stable at 2–8 °C away from direct light; reconstituted solution is best used within 3–4 weeks. Delivery across Indonesia using secure packaging.
For in-vitro and laboratory research use only.